Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is a safe and effective treatment for severe alopecia areata.

People with alopecia areata may have a higher risk of thyroid diseases.

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

A 4-year-old girl had a rare hair disorder affecting only part of her scalp.

Oral steroids may effectively treat recurrent intussusception in children with ILH, possibly avoiding surgery.

A new IL6ST gene variant may cause a unique form of hyper-IgE syndrome with skin abscesses and high IgE levels.

Baricitinib can cause excessive hair growth.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

High-dose radioactive iodine therapy does not harm fertility in thyroidectomy patients.

Ritlecitinib was generally well tolerated in children with alopecia areata.

Corticosteroid therapy for alopecia areata can cause severe hip bone damage.

An 87-year-old man showed unusual signs of Hodgkin lymphoma, primarily high calcium levels, which improved after treatment and revealed the disease.

Managing multiple autoimmune diseases in one patient is extremely challenging.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

Intralesional vitamin D3 is a safe, effective treatment for patchy alopecia areata.

Most alopecia areata patients in the study were women, aged 15-49, with patchy hair loss and often had other health conditions.

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Areata-like lupus can mimic alopecia areata but is a form of cutaneous lupus erythematosus.

Upadacitinib effectively treats psoriasis and lichen planus together.

Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Hair thinning and loss in a girl with a rare metabolic disorder was linked to her condition.